Promising new combo aims to shrink lymphoma before transplant
NCT ID NCT05821088
First seen Nov 20, 2025 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests a two-step treatment for people with large B-cell lymphoma that has returned or not responded to initial therapy. First, patients receive a combination of tafasitamab (an antibody that targets cancer cells) and lenalidomide (a drug that helps the immune system fight cancer). Then, they receive tafasitamab plus a standard chemotherapy regimen called ICE. The goal is to achieve complete remission before a stem cell transplant. About 37 adults who are eligible for transplant will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.